AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3018068
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (30 ml of 2.39 M, 6.17 g)
Trial: 3018068
Drug: Aluminum-magnesium antacid
RxNorm normalized name: ALUMINUM/MAGNESIUM HYDROXIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum-magnesium antacid (30 ml equivalent to 71.7 mmol of in vitro buffer)
Trial: 22375574
Drug: Small changes
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small changes weight loss program (3-month intervention with bi-weekly phone calls for 6 months)
Trial: 15941977
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g of alcohol per day (control)
Trial: 10339777
Drug: Etidronate therapy
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etidronate therapy (400 mg/d for 14 days with 76-day intervals, plus 500 mg of supplemental calcium per day)
Trial: 8954030
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg aldosterone iv
Trial: 2347114
Drug: 1% ciclopiroxolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% ciclopiroxolamine solution
Trial: 7028051
Drug: 1% ciclopiroxolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% ciclopiroxolamine cream
Trial: 7028051
Drug: 1% tolnaftate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% tolnaftate solution
Trial: 3530834
Drug: 1% clotrimazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% clotrimazole cream
Trial: 14972467
Drug: Genistein-rich extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genistein-rich extract (3 capsules daily for 6 months)
Trial: 9134943
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% penciclovir cream
Trial: 10302355
Drug: Sequential protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential protocol using anti-lymphocyte serum (ALS) followed by cyclosporine from the third post-graft month onwards
Trial: 10302355
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with ALS alone
Trial: 25023098
Drug: 9 mL
RxNorm normalized name: ethanol 6.9 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mL agitated saline solution with 1 mL air without the Valsalva maneuver (ASwoVM)
Trial: 25023098
Drug: 9 mL
RxNorm normalized name: ethanol 6.9 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mL agitated saline solution with 1 mL air with the Valsalva maneuver (ASwVM)
Trial: 25023098
Drug: 9 mL
RxNorm normalized name: ethanol 6.9 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mL agitated saline solution, 1 mL air and a drop of the patient's blood without the Valsalva maneuver (ASbwoVM)
Trial: 25023098
Drug: 9 mL
RxNorm normalized name: ethanol 6.9 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mL agitated saline solution, 1 mL air and a drop of the patient's blood, with the Valsalva maneuver (ASbwVM)
Trial: 17825122
Drug: Multi-faceted intervention
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-faceted intervention (educational/CBT workbook, educational visit to consultants, reminder system on medication charts)
Trial: 10227804
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g IVIG/kg/month
Trial: 10227804
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g IVIG/kg/month
Trial: 10227804
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 g iv albumin/kg/month)
Trial: 8693937
Drug: Concerns about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concerns about safety of oral contraceptives
Trial: 28127204
Drug: LAM +
RxNorm normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LAM + vaccine
Trial: 26265560
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy with good adherence
Trial: 19607951
Drug: Virosomal vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virosomal vaccine (Inflexal V)
Trial: 19607951
Drug: Standard subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard subunit vaccine (Influvac)
Trial: 7852064
Drug: Low-dose group,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose group, 50 mg elemental iron + 60 mg ascorbic acid in a multi‐vitamin daily
Trial: 7852064
Drug: Usual-dose group,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual-dose group, 200 mg elemental iron daily
Trial: 2682011
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's lactate solution plus 50 gm of albumin (group A)
Trial: 2682011
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's lactate solution alone (group B)
Trial: 1253701
Drug: Combined preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined preparation containing 250 mg clofibrate and 180 mg inositol nicotinate
Trial: 1253701
Drug: Clofibrate alone
RxNorm normalized name: Clofibrate
DrugBank: Clofibrate (DB00636)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clofibrate alone in double doses
Trial: 1253701
Drug: Combined preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined preparation (doubled dose)
Trial: 1253701
Drug: Combined preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined preparation
Trial: 29258812
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg bevacizumab with FOLFIRI
Trial: 22289674
Drug: H2-receptor antagonists
RxNorm normalized name: H2-receptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-receptor antagonists (H2RA) administered per os as a single dose immediately before surgery
Trial: 22289674
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitors (PPI) administered in two oral doses (the night before and on the morning of surgery)
Trial: 22289674
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitors (PPI) administered as a single intravenous infusion
Trial: 22289674
Drug: H2-receptor antagonists
RxNorm normalized name: H2-receptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-receptor antagonists (H2RA) administered in two doses (the night before and on the morning of surgery)
Trial: 20809746
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of implant type, preoperative knee joint loading patterns during gait, and body mass index
Trial: 12874608
Drug: Valsartan in
RxNorm normalized name: Product containing valsartan in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan in combination with hydrochlorothiazide (n=276)
Trial: 12874608
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (Control group, n=27)
Trial: 10984366
Drug: Oxitropium bromide
RxNorm normalized name: oxitropium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxitropium bromide (100 microg/actuation) plus salbutamol (100 microg/actuation) administered as 4 puffs every 20 minutes for 3 doses.
Trial: 10984366
Drug: Salbutamol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (100 microg/actuation) alone administered as 4 puffs every 20 minutes for 3 doses.
Trial: 8560674
Drug: Bicalutamide 50
RxNorm normalized name: bicalutamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 50 mg/day for 12 weeks
Trial: 8560674
Drug: Bicalutamide 100-200
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bicalutamide 100-200 mg/day
Trial: 8560674
Drug: Bicalutamide up
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bicalutamide up to 450 mg daily
Trial: 1832346
Drug: Dianette +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dianette + 2 mg CPA
Trial: 1832346
Drug: Dianette +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dianette + 20 mg CPA
Trial: 1832346
Drug: Dianette +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dianette + 100 mg CPA
Trial: 30617197
Drug: obinutuzumab plus
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy
Trial: 30239561
Drug: 3-hydroxybutyrate (3OHB)
RxNorm normalized name: 2-Amino-3-hydroxybutyric acid
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-hydroxybutyrate (3OHB) infusion
Trial: 30239561
Drug: Nonesterified fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonesterified fatty acids (Intralipid) infusion
Trial: 26991329
Drug: 30-min plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-min plasma glucose (30-min PG) tertiles: T1 < 9.1 mmol/L, T2 9.2-10.4 mmol/L, T3 ≥ 10.4 mmol/L
Trial: 24913484
Drug: Energy drink
RxNorm normalized name: Boost Energy Drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy drink (500 ml containing 160 mg of caffeine)
Trial: 24913484
Drug: Energy drink
RxNorm normalized name: Boost Energy Drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy drink + Rest (500 ml of energy drink and 10 min rest after 100 min of driving)
Trial: 24913484
Drug: Placebo drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drink (500 ml)
Trial: 11880561
Drug: Oat consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat consumption (14 g/d of dietary fiber, 5.5 g beta-glucan)
Trial: 11880561
Drug: Wheat cereals
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat cereals (14 g/d of dietary fiber, no beta-glucan)
Trial: 8566890
Drug: Single-donor fresh
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-donor fresh frozen plasma (FFP) substitution, total of 42 doses at a median of 10 (5-20) mliter/kg.
Trial: 2278982
Drug: Inpatient family
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient family intervention (IFI) added to medication during the inpatient phase of treatment.
Trial: 7193668
Drug: Intravenous Dalacin
RxNorm normalized name: Dalacin T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Dalacin C and Spectacilline for five days postoperatively
Trial: 7193668
Drug: Taurolin administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurolin administered by intraperitoneal route
Trial: 31792863
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group received normal care plus HCV antibody tests ordered and customized messages sent through their tPHR inviting them to go directly to the lab for HCV screening over a 12-week period.
Trial: 15936996
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of pravastatin daily
Trial: 31190609
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment (both atorvastatin and pravastatin)
Trial: 23979564
Drug: Class III
RxNorm normalized name: HLA class III antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Class III anti‐arrhythmic drugs at baseline
Trial: 23979564
Drug: Oral anti‐coagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anti‐coagulation (OAC) without anti‐platelet drugs
Trial: 23979564
Drug: Drug conversions
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug conversions
Trial: 21131556
Drug: BMS-641988 (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-641988 (daily doses escalated from 5 to 150 mg)
Trial: 15588464
Drug: Cetrorelix 3
RxNorm normalized name: cetrorelix 3 mg subcutaneous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrorelix 3 mg on stimulation day 7 with r-hLH 150 IU on days 7-10 (n = 25)
Trial: 15588464
Drug: Cetrorelix 3
RxNorm normalized name: cetrorelix 3 mg subcutaneous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrorelix 3 mg on stimulation day 7 without r-hLH on days 7-10 (n = 24)
Trial: 31998847
Drug: Aspirin withdrawal
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin withdrawal
Trial: 22425883
Drug: Naproxcinod, Naproxen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxcinod, Naproxen, Ibuprofen
Trial: 28073964
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg tenofovir disoproxil fumarate/400 mg emtricitabine
Trial: 18309452
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg hydrocortisone (HC) replacement therapy on the day of surgery, tapered off thereafter
Trial: 18309452
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg hydrocortisone (HC) replacement therapy
Trial: 16540883
Drug: Famciclovir 250
RxNorm normalized name: famciclovir 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famciclovir 250 mg bid for 16 weeks
Trial: 16540883
Drug: Valacyclovir 500
RxNorm normalized name: valacyclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 500 mg qd for 16 weeks
Trial: 16540883
Drug: Famciclovir 250
RxNorm normalized name: famciclovir 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famciclovir 250 mg bid for 10 weeks
Trial: 16540883
Drug: Valacyclovir 500
RxNorm normalized name: valacyclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 500 mg qd for 10 weeks
Trial: 10090428
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg twice daily for 10 days
Trial: 23934773
Drug: low-fat, high-complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low-fat, high-complex carbohydrate diet supplemented with 1.24 g/day of long-chain n-3 PUFA
Trial: 16231256
Drug: Other Licensed
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other Licensed Antifungal Therapies (OLAT) after amphotericin B deoxycholate
Trial: 16231256
Drug: Salvage therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage therapy with lipid formulation of amphotericin B after initial treatment with amphotericin B deoxycholate
Trial: 17342994
Drug: Reinhartdt and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinhartdt and sea cucumber capsule (RSC) combined with Donepezil
Trial: 17342994
Drug: Reinhartdt and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinhartdt and sea cucumber capsule (RSC)
Trial: 11673815
Drug: Ritonavir 200
RxNorm normalized name: lopinavir-ritonavir 200 mg-50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir 200 mg bid + saquinavir 600 mg bid (Rito-Saq)
Trial: 11673815
Drug: Nelfinavir 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelfinavir 1,000 mg bid + saquinavir 600 mg bid (Nelf-Saq)
Trial: 3197710
Drug: FDDF oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDDF oral administration of lorazepam 4 mg
Trial: 3197710
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of lorazepam 4 mg
Trial: 18579216
Drug: Quetiapine (400-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (400-800 mg/day) plus lithium/divalproex
Trial: 12885680
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg enoxaparin sodium
Trial: 12885680
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg enoxaparin
Trial: 12885680
Drug: Oral tenoxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tenoxicam
Trial: 10558945
Drug: Ciprofloxacin (single-dose)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (single-dose)
Trial: 8914204
Drug: Tamoxifen in
RxNorm normalized name: Product containing tamoxifen in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen in combination with chemotherapy for metastatic melanoma
Trial: 8914204
Drug: Steroid hormones
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Steroid hormones
Trial: 1677820
Drug: Pipecuronium (PIP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipecuronium (PIP), 0.10 mg/kg
Trial: 1677820
Drug: Vecuronium (V),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (V), 0.12 mg/kg
Trial: 30448030
Drug: TURBT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TURBT plus immediate postoperative epirubicin (50 mg)
Trial: 28070882
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 180 mg ticagrelor pre-PCI, followed by ticagrelor 90 mg twice daily post-PCI (group TT)
Trial: 28070882
Drug: Maintenance dose
RxNorm normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance dose of ticagrelor 90 mg twice daily (group CT)
Trial: 28070882
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg daily post-PCI (group CC)
Trial: 28070882
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of ticagrelor (group TT)
Trial: 25606328
Drug: Low Level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Level Laser Therapy (LLLT) and splinting
Trial: 31662030
Drug: Chemotherapy or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy or surgery only (based on model recommendation)
Trial: 30646158
Drug: Late parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late parenteral nutrition (PN) initiated after 1 week
Trial: 30646158
Drug: Early parenteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early parenteral nutrition (PN) initiated within 24 hours
Trial: 12925054
Drug: Motivational and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational and solution-focused therapy group intervention
Trial: 9082675
Drug: Tedisamil 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tedisamil 0.3 mg/kg BW
Trial: 9082675
Drug: Tedisamil 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tedisamil 0.4 mg/kg BW
Trial: 7423284
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 tablets administered intravaginally
Trial: 31778436
Drug: High-intensity laser
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity laser therapy at 1064 nm and 60 J/cm2 for 10 min (HILT)
Trial: 31778436
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy at 785 nm and 8 J/cm2 for 8 min (LLLT)
Trial: 28179223
Drug: Whole grain-rich
RxNorm normalized name: rice (whole grain) allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole grain-rich diet (207 ± 39 g whole grains plus 40 ± 5 g dietary fiber/d)
Trial: 28179223
Drug: Refined grain-based
RxNorm normalized name: barley grain
DrugBank: Barley (DB10506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refined grain-based diet (0 g whole grains plus 21 ± 3 g dietary fiber/d)
Trial: 25894405
Drug: Probiotics (Lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Lactobacillus acidophilus, L. plantarum, Bifidobacterium lactis, Saccharomyces boulardii)
Trial: 12729938
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of sustained‐release melatonin
Trial: 9917048
Drug: 4% cocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% cocaine solution for 10 min (160 mg)
Trial: 9917048
Drug: 4% cocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% cocaine solution for 20 min (160 mg)
Trial: 9917048
Drug: 10% cocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% cocaine solution for 20 min (400 mg)
Trial: 2186909
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily netilmicin (n = 98)
Trial: 2186909
Drug: Thrice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice daily netilmicin (n = 99)